Can-Fite BioPharma Ltd (CANF) Stock Forecast and Price Target (2026)

Sell-side coverage follows trading volume and banking relationships, so smaller companies, recent listings, and names outside the major indices often carry little or none. That is the situation with CANF. It says nothing about the quality of the business, but it does mean there is no informed average to anchor to, and that any single target you find elsewhere is one analyst's model rather than a consensus.

Figures are approximate and tied to the asOf date; verify live numbers before acting. For a pre-revenue biotech, traditional valuation metrics such as P/E do not apply, because there are no earnings; what matters is cash runway, the probability and timing of clinical readouts, and dilution. As of October 2026 the market values Can-Fite at roughly $5.6 million, about the size of its mid-year cash balance, which means the market is assigning little value to the pipeline while it waits for the liver-cancer interim analysis and the Q1 2027 psoriasis interim results.

For the fiscal year ending Dec 2026, the one analyst publishing estimates on CANF expects earnings of -$2.04 per share and revenue of $404 thousand (-0.2%).

Estimates are the most widely published forecast there is: many more analysts model a company's earnings than publish a price target on it. They are also revised constantly, and the direction of those revisions into a report is often more informative than the level.

Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering CANF do not put out a 2030 number. Anything presenting one is extrapolating a growth rate rather than reporting research, and a figure produced that way tells you about the assumption chosen, not about the company.

What can be said over a long horizon is what the current price already assumes about the business, which is a question the filings answer and a forecast cannot.

That is the more useful frame for a ten-year question. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether Can-Fite BioPharma Ltd can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.

In short: the drivers cited most often are Namodenoson liver-cancer (HCC) Phase 3 readout, Broader Namodenoson pipeline (MASH and pancreatic cancer), Piclidenoson Phase 3 in psoriasis. The risk cited most often against it is this is a highly speculative micro-cap with concentrated, binary risk.

Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the CANF is it a buy page. This page deliberately stops at the numbers.